<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02874248</url>
  </required_header>
  <id_info>
    <org_study_id>MIT-Es0001-C103</org_study_id>
    <secondary_id>2016-000861-22</secondary_id>
    <nct_id>NCT02874248</nct_id>
  </id_info>
  <brief_title>E4/DRSP Single and Multiple Dose PK and Early QT Study</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Parallel, Single Center Study to Investigate the Pharmacokinetics, Safety, Tolerability, and QT Concentration-effect Modelling of Estetrol in Combination With Drospirenone After Single and Multiple Dosing in Healthy Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Estetra</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Estetra</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is conducted to evaluate the effect of single and multiple therapeutic and&#xD;
      supratherapeutic oral doses of E4/DRSP combinations on PK parameters, safety, tolerability&#xD;
      and on cardiac repolarization, as detected by QT interval corrected with Fridericia's formula&#xD;
      (QTcF).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a randomized, double-blind, placebo-controlled, parallel, single center study in&#xD;
      healthy female subjects. A total of 42 female subjects will be enrolled in 3 groups of 14&#xD;
      subjects each. A potential fourth group of 14 healthy female subjects may be added. In each&#xD;
      group, subjects will be randomized in a 2.5 to 1 ratio between active (n=10) and placebo&#xD;
      (n=4).&#xD;
&#xD;
      Subjects will receive a single dose on Day 1 and, after a washout of at least 14 days,&#xD;
      multiple doses on 14 consecutive days from Days 15 to 28.&#xD;
&#xD;
      Group 1 and Group 2 may be dosed in parallel. After completion of Group 1 and Group 2, a Dose&#xD;
      Escalation Report (DER), including PK data up to at least 24 hours post-last dose, will be&#xD;
      prepared by the Principal Investigator (PI). Escalation to the planned dose level of 60 mg&#xD;
      E4/12 mg DRSP will only proceed if the safety and tolerability of the dose levels of 15 mg&#xD;
      E4/3 mg DRSP and 30 mg E4/6 mg DRSP up to 24 hours post-last dose, are acceptable to the PI&#xD;
      and the Sponsor and, if deemed necessary by the Independent Ethics Committee (IEC) following&#xD;
      their review of the protocol, after a statement of no objection of the DER from the IEC.&#xD;
&#xD;
      After completion of Group 3, a second DER, including PK data, will be prepared by the PI. If&#xD;
      in Group 3 the expected exposure level of approximately 4 times the exposure of Group 1 is&#xD;
      not achieved, and treatment in Group 3 is well tolerated, an additional group with 14&#xD;
      subjects may be enrolled, using a dose level that is estimated to result in at least 4 times&#xD;
      the exposure after administration of the 15 mg E4/3 mg DRSP therapeutic dose.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Actual">November 21, 2016</completion_date>
  <primary_completion_date type="Actual">November 21, 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax: Maximum observed plasma concentration of E4 and DSRP</measure>
    <time_frame>On day 1 and day 28 (steady state)</time_frame>
    <description>PK sampling on day 1, 2-3, 4-8, 16-25, 26-27, 28, 29, 30, 31-35</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax: time to attain maximum observed plasma concentration of E4 and DSRP</measure>
    <time_frame>On day 1 and day 28 (steady state)</time_frame>
    <description>PK sampling on day 1, 2-3, 4-8, 16-25, 26-27, 28, 29, 30, 31-35</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-t: Area under the plasma concentration-time curve up to time t, where t is the last point with concentrations above the lower limit of quantitation (LLOQ) - for E4 and DSRP</measure>
    <time_frame>On day 1 and day 28 (steady state)</time_frame>
    <description>PK sampling on day 1, 2-3, 4-8, 16-25, 26-27, 28, 29, 30, 31-35</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-24: area under the plasma concentration-time curve up to time 24 hours (where 24 hours is the dosing interval) using linear-log trapezoidal rule - for E4 and DSRP</measure>
    <time_frame>On day 1 only</time_frame>
    <description>PK sampling on day 1, 2-3, 4-8, 16-25, 26-27, 28, 29, 30, 31-35</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-inf: Area under the plasma concentration-time curve from time 0 to infinity calculated as: AUC0-inf = AUC0-t + Clast/kel, where Clast is the last measurable plasma concentration</measure>
    <time_frame>On day 1 only</time_frame>
    <description>PK sampling on day 1, 2-3, 4-8, 16-25, 26-27, 28, 29, 30, 31-35</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Kel: terminal elimination rate constant of E4 and DSRP</measure>
    <time_frame>On day 1 and day 28 (steady state)</time_frame>
    <description>PK sampling on day 1, 2-3, 4-8, 16-25, 26-27, 28, 29, 30, 31-35</description>
  </primary_outcome>
  <primary_outcome>
    <measure>T1/2: terminal elimination half-life of E4 and DSRP, calculated as 0.693/kel</measure>
    <time_frame>On day 1 and day 28 (steady state)</time_frame>
    <description>PK sampling on day 1, 2-3, 4-8, 16-25, 26-27, 28, 29, 30, 31-35</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-tau: Area under the plasma concentration time curve over a dosing interval tau - of E4 and DSRP</measure>
    <time_frame>On day 28 only</time_frame>
    <description>PK sampling on day 1, 2-3, 4-8, 16-25, 26-27, 28, 29, 30, 31-35</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ra: Accumulation ratio for AUC</measure>
    <time_frame>On day 1 and day 28 (steady state)</time_frame>
    <description>PK sampling on day 1, 2-3, 4-8, 16-25, 26-27, 28, 29, 30, 31-35</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of adverse events and number of subjects with AEs as a measure of safety and tolerability</measure>
    <time_frame>From admission until follow-up visit (between day 37 and 41)</time_frame>
    <description>Any clinically significant observations in results of clinical laboratory tests, 12-lead ECGs, echocardiography, continuous cardiac monitoring (Holter monitoring), vital signs, or physical examinations will be recorded as AEs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>deltaQTcF as measured by Holter monitoring (continuous cardiac monitoring)</measure>
    <time_frame>Time matched on day -1 (for baseline measurements) and on day 28: 1 hour pre-dose until 24h post-dose</time_frame>
    <description>To define the effect of E4 in combination with DRSP on QT interval corrected with Fridericia's formula (QTcF)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ECG parameters</measure>
    <time_frame>Once during screening period; on day -2, 2, 15, 28, 29; once between day 2-3 and once between day 37 and 41 (follow-up)</time_frame>
    <description>To define the effect of E4 in combination with DRSP on heart rate (HR), PR, and QRS</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">55</enrollment>
  <condition>Contraception</condition>
  <arm_group>
    <arm_group_label>Group 1: 15 mg E4/3 mg DRSP (n=10)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>a single oral dose of 15 mg E4/3 mg DRSP (n=10) followed, after a washout of at least 14 days, by multiple oral doses of 15 mg E4/3 mg DRSP (n=10) once daily for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group1: Placebo (n=4)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>a single oral dose of a placebo which visually matches the active medication, followed, after a washout of at least 14 days, by multiple oral doses of matching placebo once daily for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: 30 mg E4/6 mg DRSP (n=10)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>a single oral dose of 30 mg E4/6 mg DRSP, followed, after a washout of at least 14 days, by multiple oral doses of 30 mg E4/6 mg DRSP once daily for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: Placebo (n=4)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>a single oral dose of a placebo which visually matches the active medication, followed, after a washout of at least 14 days, by multiple oral doses of matching placebo once daily for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3: 60 mg E4/12 mg DRSP (n=10)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>a single oral dose of 60 mg E4/12 mg DRSP, followed, after a washout of at least 14 days, by oral doses of 60 mg E4/12 mg DRSP once daily for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3: Placebo (n=4)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>a single oral dose of a placebo which visually matches the active medication, followed, after a washout of at least 14 days, by multiple oral doses of matching placebo once daily for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4: 75 mg E4/15 mg DRSP (n=9)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>a single oral dose of 75 mg E4/15 mg DRSP, followed, after a washout of at least 14 days, by oral doses of 75 mg E4/15 mg DRSP once daily for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4: Placebo (n=4)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>a single oral dose of a placebo which visually matches the active medication, followed, after a washout of at least 14 days, by multiple oral doses of matching placebo once daily for 14 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>15 mg E4/3 mg DRSP</intervention_name>
    <description>a single oral dose of 15 mg E4/3 mg DRSP (n=10) followed, after a washout of at least 14 days, by multiple oral doses of 15 mg E4/3 mg DRSP (n=10) once daily for 14 days</description>
    <arm_group_label>Group 1: 15 mg E4/3 mg DRSP (n=10)</arm_group_label>
    <other_name>15 mg estetrol and 3 mg drospirenone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>30 mg E4/6 mg DRSP</intervention_name>
    <description>a single oral dose of 30 mg E4/6 mg DRSP, followed, after a washout of at least 14 days, by multiple oral doses of 30 mg E4/6 mg DRSP once daily for 14 days</description>
    <arm_group_label>Group 2: 30 mg E4/6 mg DRSP (n=10)</arm_group_label>
    <other_name>30 mg estetrol and 6 mg drospirenone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>60 mg E4/12 mg DRSP</intervention_name>
    <description>a single oral dose of 60 mg E4/12 mg DRSP, followed, after a washout of at least 14 days, by oral doses of 60 mg E4/12 mg DRSP once daily for 14 days</description>
    <arm_group_label>Group 3: 60 mg E4/12 mg DRSP (n=10)</arm_group_label>
    <other_name>60 mg estetrol and 12 mg drospirenone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Visually matching placebo</intervention_name>
    <description>a single oral dose of a placebo which visually matches the active medication, followed, after a washout of at least 14 days, by multiple oral doses of matching placebo once daily for 14 days</description>
    <arm_group_label>Group 2: Placebo (n=4)</arm_group_label>
    <arm_group_label>Group 3: Placebo (n=4)</arm_group_label>
    <arm_group_label>Group 4: Placebo (n=4)</arm_group_label>
    <arm_group_label>Group1: Placebo (n=4)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>75 mg E4/15 mg DRSP</intervention_name>
    <description>a single oral dose of 75 mg E4/15 mg DRSP, followed, after a washout of at least 14 days, by oral doses of 75 mg E4/15 mg DRSP once daily for 14 days</description>
    <arm_group_label>Group 4: 75 mg E4/15 mg DRSP (n=9)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Gender : Healthy female subject&#xD;
&#xD;
          2. Age : 18-50 years, inclusive&#xD;
&#xD;
          3. Body mass index (BMI) : 18.0-35.0 kg/m2&#xD;
&#xD;
          4. At screening, female subjects must be non-pregnant and non-lactating, or of&#xD;
             non-childbearing potential&#xD;
&#xD;
          5. Willing to use a double-barrier method of contraception from screening until 90 days&#xD;
             after the follow up visit.&#xD;
&#xD;
          6. Willingness to abstain from alcohol and grapefruit (juice) from 48 hours prior to&#xD;
             admission into the clinical research center up to follow-up.&#xD;
&#xD;
          7. Normal resting supine blood pressure and pulse showing no clinically relevant&#xD;
             deviations as judged by the PI at screening.&#xD;
&#xD;
          8. Computerized (12-lead) ECG recording without signs of clinically relevant pathology at&#xD;
             screening&#xD;
&#xD;
          9. Willing and able to sign the ICF.&#xD;
&#xD;
         10. Willing and able to comply with the study procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Postmenopausal status&#xD;
&#xD;
          2. History or presence of clinically relevant disease of any major system organ class&#xD;
             (e.g., cardiovascular, pulmonary, renal, hepatic, gastrointestinal, reproductive,&#xD;
             endocrinological, neurological, psychiatric or orthopedic disease) as judged by the PI&#xD;
&#xD;
          3. Condition of hyperkalemia resulting from renal insufficiency, hepatic dysfunction,&#xD;
             adrenal insufficiency or medication intake&#xD;
&#xD;
          4. Previous participation in the current study&#xD;
&#xD;
          5. Use of:&#xD;
&#xD;
               -  combined contraceptives (i.e., COC, Nuvaring®) within 28 days prior to the first&#xD;
                  dose administration until study completion&#xD;
&#xD;
               -  progestogen-only contraceptive methods (e.g., minipill, implant, or hormonal&#xD;
                  intrauterine system) within 28 days prior to the first dose administration until&#xD;
                  study completion&#xD;
&#xD;
               -  depot progestogen preparations or an injectable hormonal method of contraception&#xD;
                  (e.g., Depo-Provera®) within 6 months prior to the first dose until study&#xD;
                  completion&#xD;
&#xD;
          6. Use of:&#xD;
&#xD;
               -  any prescription drugs or herbal supplements acting on CYP3A4 functions (e.g.,&#xD;
                  St. John's Wort) within 28 days prior to the first study dose administration&#xD;
                  until study completion&#xD;
&#xD;
               -  any over-the-counter medication or dietary supplements (vitamins included) within&#xD;
                  14 days prior to the first study dose administration until study completion.&#xD;
&#xD;
          7. Use of any tobacco products within the last 3 months prior to the first admission&#xD;
&#xD;
          8. History of alcohol abuse or drug addiction (including soft drugs like cannabis&#xD;
             products)&#xD;
&#xD;
          9. Positive drug screening&#xD;
&#xD;
         10. Positive screen for hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV)&#xD;
             antibodies or human immunodeficiency virus (HIV) 1 and 2 antibodies&#xD;
&#xD;
         11. Participation in an investigational drug study within 60 days prior to the first drug&#xD;
             administration in the current study&#xD;
&#xD;
         12. History of relevant drug and/or food allergies&#xD;
&#xD;
         13. Donation or loss of more than 100 mL of blood within 60 days prior to the first drug&#xD;
             administration. Donation or loss of more than 1.0 L of blood in the 10 months prior to&#xD;
             the first drug administration in the current study&#xD;
&#xD;
         14. Significant and/or acute illness within 5 days prior to the first drug administration&#xD;
             that may impact safety assessments, as judged by the PI&#xD;
&#xD;
         15. History and/or family history of congenital long QT syndrome, unexplained syncope or&#xD;
             other additional risks for Torsade de Pointes, or sudden death&#xD;
&#xD;
         16. History or presence of hormone-related malignancy treated or not, whatever the time of&#xD;
             onset. History of malignancy of any other organ system (other than localized basal&#xD;
             cell carcinoma of the skin), treated or untreated, within the past 5 years prior to&#xD;
             screening&#xD;
&#xD;
         17. History of migraine with aura&#xD;
&#xD;
         18. Any surgical or medical condition that could significantly alter the absorption,&#xD;
             distribution, metabolism, or excretion of drugs, or which may jeopardize the subject&#xD;
             in case of participation in the study&#xD;
&#xD;
         19. Contraindications for the use of contraceptive steroids&#xD;
&#xD;
         20. Sponsor employees or clinical site personnel directly affiliated with this study&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeroen van de Wetering, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>PRA Health Sciences</affiliation>
  </overall_official>
  <verification_date>August 2016</verification_date>
  <study_first_submitted>August 9, 2016</study_first_submitted>
  <study_first_submitted_qc>August 16, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 22, 2016</study_first_posted>
  <last_update_submitted>April 20, 2017</last_update_submitted>
  <last_update_submitted_qc>April 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Drospirenone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

